26 April 2013
April 26, 2013.
Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX) today announced that the Company’s Board of Directors has nominated Vicente Anido, Jr., PhD., to be elected to the Board. Dr. Anido is a highly respected and experienced leader in the ophthalmology sector. He most recently served as President and Chief Executive Officer of ISTA Pharmaceuticals prior to its acquisition by Bausch + Lomb. The election of Dr. Anido to Nicox’s Board will be voted on at the Company’s 2013 Ordinary Shareholder Meeting, which will be convened for June 6, 2013.
“The Board is pleased to propose Vince Anido as a Board member of Nicox. Vince has a wealth of experience in the management of pharmaceutical companies, particularly in the ophthalmic area. We believe he would be a significant addition to the existing strength and combined experience of the Nicox Board as we work towards building an international ophthalmology business,” said Michele Garufi, Chief Executive Officer of Nicox.
About Vicente Anido, Jr.
From 2001 to 2012, Dr. Anido was President, Chief Executive Officer and a Director of ISTA Pharmaceuticals, a US-based ophthalmic pharmaceutical company. Prior to this, he was general partner of Windamere Venture Partners, served as President and CEO of CombiChem, Inc., a biotechnology company, and was President of the Americas Region of Allergan, a specialty pharmaceutical company focusing on ophthalmology, dermatology and neuromuscular indications.
Dr. Anido currently serves on the Board of Directors of QLT Inc. and Depomed Inc., two NASDAQ-listed pharmaceutical companies, and was recently named Chairman of the Board of Directors of Aerie Pharmaceuticals, a US private ophthalmic company.
Dr. Anido received a B.S. in Pharmacy, an M.S. in Pharmacy Administration from West Virginia University and a Ph.D. in Pharmacy Administration from the University of Missouri.